We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Rapid Diagnostics Platform Leverages Graphene-Based Biosensors for Real-Time Disease Detection

By LabMedica International staff writers
Posted on 08 Jun 2023
Print article
Image: Graphene-based biosensors for medical devices can be used to diagnose a variety of diseases at POC (Photo courtesy of Freepik)
Image: Graphene-based biosensors for medical devices can be used to diagnose a variety of diseases at POC (Photo courtesy of Freepik)

A revolutionary graphene-based technology enables testing for a broad range of indications using a variety of sample types in less than five minutes at POC, placing high-performance diagnostics directly in the hands of medical professionals.

GrapheneDx (Boston MA, USA), an in vitro diagnostics company, is focusing on improving diagnostic capability at the point of care by industrializing graphene-based biosensors for medical devices used to diagnose a variety of diseases. Known for its superior electrical properties, graphene - a single-atom, thick layer of carbon - enables the highly accurate detection of diverse biomolecules. The medical devices developed by GrapheneDx are designed to match lab-quality accuracy, yield results in less than five minutes, and be easy enough to be used in professional healthcare settings.

GrapheneDx has developed the GFET platform which demonstrates remarkable versatility in diagnosing various conditions such as sexually transmitted infections, respiratory and cardiac diseases, concussion, and more, using different sample types like stool, urine, swabs, blood, etc., with minimal or no sample preparation. Moreover, the platform has the capability to concurrently multiplex multiple analytes using a single patient sample. The first tests introduced by GrapheneDx will focus on the diagnosis of sexually transmitted infections, specifically Chlamydia and Gonorrhea, utilizing a noninvasive, easy-to-collect urine sample.

Related Links:
GrapheneDx 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more